Market Closed -
Nasdaq
04:00:00 2024-06-05 pm EDT
|
5-day change
|
1st Jan Change
|
43.64
USD
|
+5.56%
|
|
+3.71%
|
-27.47%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,735
|
7,175
|
8,357
|
10,938
|
7,955
|
-
|
-
|
Enterprise Value (EV)
1 |
3,233
|
6,446
|
7,855
|
9,959
|
7,212
|
7,110
|
6,822
|
P/E ratio
|
-22
x
|
-34
x
|
-35.7
x
|
-40.9
x
|
-41
x
|
-82.5
x
|
126
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
49.4
x
|
79.9
x
|
71.4
x
|
38.4
x
|
15.2
x
|
7.71
x
|
5.06
x
|
EV / Revenue
|
42.7
x
|
71.8
x
|
67.1
x
|
34.9
x
|
13.8
x
|
6.89
x
|
4.34
x
|
EV / EBITDA
|
-14.6
x
|
-17.9
x
|
-17.7
x
|
-25.4
x
|
-19.6
x
|
-52.3
x
|
36.2
x
|
EV / FCF
|
-12
x
|
-26.6
x
|
-33.1
x
|
-24.1
x
|
-16.3
x
|
-64.6
x
|
32.5
x
|
FCF Yield
|
-8.31%
|
-3.76%
|
-3.02%
|
-4.15%
|
-6.12%
|
-1.55%
|
3.07%
|
Price to Book
|
26.7
x
|
30.5
x
|
-
|
17.5
x
|
10.4
x
|
7.92
x
|
5.62
x
|
Nbr of stocks (in thousands)
|
132,638
|
153,946
|
167,403
|
181,789
|
182,283
|
-
|
-
|
Reference price
2 |
28.16
|
46.61
|
49.92
|
60.17
|
43.64
|
43.64
|
43.64
|
Announcement Date
|
3/18/21
|
3/18/22
|
3/30/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
75.68
|
89.79
|
117
|
285.1
|
524.5
|
1,031
|
1,573
|
EBITDA
1 |
-220.8
|
-360.6
|
-443.2
|
-392.1
|
-368.5
|
-136
|
188.5
|
EBIT
1 |
-229.2
|
-373
|
-455.8
|
-412.6
|
-394.1
|
-163.4
|
169.7
|
Operating Margin
|
-302.87%
|
-415.44%
|
-389.58%
|
-144.69%
|
-75.15%
|
-15.85%
|
10.79%
|
Earnings before Tax (EBT)
1 |
-307.6
|
-386.2
|
-445.7
|
-520.1
|
-350.1
|
-163.2
|
166.1
|
Net income
1 |
-303.5
|
-386.2
|
-446.3
|
-518.3
|
-346.8
|
-156.5
|
148.3
|
Net margin
|
-401.02%
|
-430.12%
|
-381.48%
|
-181.75%
|
-66.12%
|
-15.17%
|
9.43%
|
EPS
2 |
-1.280
|
-1.370
|
-1.400
|
-1.470
|
-1.065
|
-0.5291
|
0.3451
|
Free Cash Flow
1 |
-268.8
|
-242.4
|
-237
|
-413.4
|
-441.3
|
-110
|
209.6
|
FCF margin
|
-355.14%
|
-269.92%
|
-202.57%
|
-144.97%
|
-84.15%
|
-10.66%
|
13.32%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
111.19%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
141.32%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/18/21
|
3/18/22
|
3/30/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
39
|
40.83
|
11.97
|
36.34
|
73.33
|
96.01
|
79.46
|
93.99
|
119.9
|
133.5
|
177.5
|
188.8
|
241.8
|
EBITDA
1 |
-114.2
|
-
|
-116.1
|
-
|
-
|
-53.64
|
-
|
-48.59
|
-106
|
-109.1
|
-100.5
|
-56.7
|
-56.73
|
EBIT
1 |
-117.5
|
-76
|
-125.5
|
-106.9
|
-104.3
|
-56.82
|
-141
|
-54.31
|
-95.4
|
-106
|
-93.86
|
-76.03
|
-36.47
|
Operating Margin
|
-301.22%
|
-186.16%
|
-1,048.6%
|
-294.09%
|
-142.25%
|
-59.18%
|
-177.43%
|
-57.79%
|
-79.56%
|
-79.4%
|
-52.89%
|
-40.27%
|
-15.08%
|
Earnings before Tax (EBT)
1 |
-88.33
|
-41.09
|
-193.1
|
-112
|
-198.8
|
-62.5
|
-146.8
|
-59.79
|
-92.93
|
-105.4
|
-92.13
|
-74.49
|
-35.17
|
Net income
1 |
-88.33
|
-41.09
|
-193.2
|
-112.1
|
-199.1
|
-62.21
|
-144.8
|
-59.79
|
-95.22
|
-106.1
|
-94.5
|
-74.56
|
-35.26
|
Net margin
|
-226.53%
|
-100.64%
|
-1,614.13%
|
-308.51%
|
-271.55%
|
-64.79%
|
-182.24%
|
-63.62%
|
-79.4%
|
-79.41%
|
-53.24%
|
-39.49%
|
-14.58%
|
EPS
2 |
-0.3000
|
-0.1300
|
-0.6200
|
-0.3400
|
-0.5700
|
-0.1700
|
-0.4000
|
-0.1600
|
-0.2704
|
-0.3091
|
-0.2806
|
-0.2060
|
-0.1120
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/18/22
|
6/1/22
|
2/17/23
|
5/18/23
|
8/15/23
|
11/20/23
|
3/11/24
|
5/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
502
|
729
|
501
|
979
|
743
|
845
|
1,132
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-269
|
-242
|
-237
|
-413
|
-441
|
-110
|
210
|
ROE (net income / shareholders' equity)
|
-284%
|
-103%
|
-59.1%
|
-51.9%
|
-34.9%
|
-17.8%
|
15.5%
|
ROA (Net income/ Total Assets)
|
-44.3%
|
-42%
|
-36.4%
|
-32.6%
|
-24%
|
-14.5%
|
11.4%
|
Assets
1 |
684.9
|
919.7
|
1,225
|
1,590
|
1,442
|
1,082
|
1,306
|
Book Value Per Share
2 |
1.050
|
1.530
|
-
|
3.440
|
4.200
|
5.510
|
7.770
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-0.9000
|
-0.8100
|
0.1800
|
Capex
1 |
45.7
|
43.9
|
35.7
|
20.1
|
49.1
|
36.1
|
38
|
Capex / Sales
|
60.45%
|
48.9%
|
30.54%
|
7.04%
|
9.37%
|
3.5%
|
2.42%
|
Announcement Date
|
3/18/21
|
3/18/22
|
3/30/23
|
3/11/24
|
-
|
-
|
-
|
Last Close Price
43.64
USD Average target price
82.53
USD Spread / Average Target +89.12% Consensus |
1st Jan change
|
Capi.
|
---|
| -27.47% | 7.95B | | +18.72% | 125B | | +14.53% | 109B | | -2.88% | 24.74B | | +2.18% | 22.67B | | -10.09% | 18.14B | | -41.04% | 16.67B | | -11.83% | 16.64B | | +1.46% | 13.45B | | +24.22% | 11.32B |
Bio Therapeutic Drugs
|